NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 270 filers reported holding NOVOCURE LTD in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $179 | -48.7% | 10,463 | +24.5% | 0.00% | -100.0% |
Q2 2023 | $349 | -23.0% | 8,401 | +11.5% | 0.00% | 0.0% |
Q1 2023 | $453 | -20.2% | 7,535 | -2.7% | 0.00% | 0.0% |
Q4 2022 | $568 | -99.9% | 7,745 | +11.5% | 0.00% | 0.0% |
Q3 2022 | $527,000 | -1.1% | 6,946 | -9.5% | 0.00% | 0.0% |
Q2 2022 | $533,000 | -22.8% | 7,674 | -8.0% | 0.00% | -50.0% |
Q1 2022 | $690,000 | +7.3% | 8,338 | -2.7% | 0.00% | +100.0% |
Q4 2021 | $643,000 | -0.8% | 8,567 | +53.5% | 0.00% | -50.0% |
Q3 2021 | $648,000 | -49.1% | 5,582 | -2.8% | 0.00% | -33.3% |
Q2 2021 | $1,273,000 | +79.0% | 5,741 | +6.7% | 0.00% | +50.0% |
Q1 2021 | $711,000 | -45.2% | 5,379 | -28.3% | 0.00% | -50.0% |
Q4 2020 | $1,297,000 | +61.3% | 7,500 | +3.7% | 0.00% | +33.3% |
Q3 2020 | $804,000 | +86.1% | 7,231 | -0.7% | 0.00% | +50.0% |
Q2 2020 | $432,000 | +38.5% | 7,285 | +57.0% | 0.00% | +100.0% |
Q1 2020 | $312,000 | -24.8% | 4,641 | -6.0% | 0.00% | -50.0% |
Q4 2019 | $415,000 | +70.8% | 4,936 | +51.3% | 0.00% | +100.0% |
Q3 2019 | $243,000 | – | 3,262 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
StepStone Group LP | 1,365,479 | $29,767,000 | 21.90% |
Tamarack Advisers, LP | 1,115,000 | $24,307,000 | 11.56% |
COURAGE CAPITAL MANAGEMENT LLC | 275,000 | $5,995,000 | 4.57% |
GREAT POINT PARTNERS LLC | 753,481 | $16,426,000,000 | 2.44% |
HARTLINE INVESTMENT CORP/ | 404,052 | $8,808,000 | 2.42% |
Pier Capital, LLC | 346,350 | $7,550,000 | 1.29% |
Rhenman & Partners Asset Management AB | 435,000 | $9,483,000 | 1.17% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 1,029,910 | $22,452,000 | 0.77% |
PEREGRINE CAPITAL MANAGEMENT LLC | 922,468 | $20,110,000 | 0.49% |
Hodges Capital Management Inc. | 285,500 | $6,224,000 | 0.49% |